POM-V Prescription Required Companion Animal

Loxicom 5 mg/ml Solution for Injection for Dogs and Cats

Active ingredient: Meloxicam

Form

Injection

Species

Cats Dogs

Manufacturer

Norbrook Laboratories Limited

VMD MA No.

02000/5006

What it's used for

Dogs: Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders. Reduction of post-operative pain and inflammation followin...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Meloxicam

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Loxicom 5 mg/ml Solution for Injection for Dogs and Cats — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 26 Mar 2026.

Dogs:
Alleviation of inflammation and pain in both acute and chronic musculo-skeletal
disorders. Reduction of post-operative pain and inflammation following orthopaedic
and soft tissue surgery.
Cats:
Reduction of post-operative pain after ovariohysterectomy and minor soft tissue
surgery.

Dogs:
Musculo-skeletal disorders: Single subcutaneous injection at a dosage of 0.2 mg
meloxicam/kg bodyweight (i.e. 0.4 ml/10 kg bodyweight). Loxicom 1.5 mg/ml oral
suspension and Loxicom 0.5 mg/ml oral suspension may be used for continuation of
treatment at a dosage of 0.1 mg meloxicam/kg bodyweight, 24 hours after
administration of the injection.
Reduction of post-operative pain (over a period of 24 hours): Single intravenous or
subcutaneous injection at a dosage of 0.2 mg meloxicam/kg bodyweight (i.e.
0.4 ml/10 kg bodyweight) before surgery, for example at the time of induction of
anaesthesia.
Cats:
Reduction of post-operative pain in cats where no oral follow-up treatment is
possible e.g. feral cats:
Single subcutaneous injection at a dosage of 0.3 mg meloxicam/kg bodyweight (i.e.
0.06 ml/kg bodyweight) before surgery, for example at the time of induction of
anaesthesia. In this case do not use oral follow up treatment.
Reduction of post-operative pain in cats when administration of meloxicam is to be
continued as an oral follow-up therapy:

Amended Pages: December 2024
AN: 01004/2024
Single subcutaneous injection at a dosage of 0.2 mg meloxicam/kg body weight (i.e.
0.04 ml/kg body weight) before surgery, for example at the time of induction of
anaesthesia.
To continue treatment for up to five days, this initial dose may be followed 24 hours
later by administration of Loxicom 0.5 mg/ml oral suspension for cats at a dosage of
0.05 mg meloxicam/kg body weight. The oral follow-up dose may be administered for
up to a total of four doses at 24 hour intervals.
Particular care should be taken with regard to the accuracy of dosing.
A suitably graduated 1 ml syringe should be used for administration of the product to
cats.
Avoid introduction of contamination during use.

Do not use in pregnant or lactating animals.
Do not use in animals suffering from gastrointestinal disorders such as irritation and
haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic
disorders.

Amended Pages: December 2024
AN: 01004/2024
Do not use in case of hypersensitivity to the active substance or to any of the
excipients.
Do not use in animals less than 6 weeks of age nor in cats of less than 2 kg.

Typical adverse reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea,
faecal occult blood, apathy and renal failure have occasionally been reported. In very
rare cases elevated liver enzymes have been reported.
In very rare cases, haemorrhagic diarrhoea, haematemesis and gastrointestinal
ulceration have been reported.
These adverse reactions occur generally within the first treatment week and are in
most cases transient and disappear following termination of the treatment but in very
rare cases may be serious or fatal.
In very rare cases anaphylactoid reactions may occur and should be treated
symptomatically.
If adverse reactions occur, treatment should be discontinued and the advice of a
veterinarian should be sought.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)

Amended Pages: December 2024
AN: 01004/2024
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports)

For post-operative pain relief in cats, safety has only been documented after
thiopental/halothane anaesthesia.

Special precautions for use in animals
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a
potential risk of renal toxicity.
During anaesthesia, monitoring and fluid therapy should be considered as standard
practice.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
Accidental self-injection may give rise to pain. People with known hypersensitivity to
NSAIDs should avoid contact with the veterinary medicinal product.
In case of accidental self-injection, seek medical advice immediately and show the
package leaflet or the label to the physician.
This product can cause eye irritation. In case of contact with the eyes, immediately
rinse thoroughly with water.

Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances
with high protein binding may compete for binding and thus lead to toxic effects.
Loxicom must not be administered in conjunction with other NSAIDs or
glucocorticosteroids. Concurrent administration of potential nephrotoxic drugs should
be avoided. In animals at anaesthetic risk (e.g. aged animals) intravenous or
subcutaneous fluid therapy during anaesthesia should be taken into consideration.
When anaesthesia and NSAID are concomitantly administered, a risk for renal
function cannot be excluded.
Pre-treatment with other anti-inflammatory substances may result in additional or
increased adverse effects and accordingly a treatment-free period with such drugs
should be observed for at least 24 hours before commencement of treatment. The
treatment-free period, however, should take into account the pharmacological
properties of the products used previously.

This veterinary medicinal product does not require any special storage conditions.

Not applicable.
5.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.